Hashan has had a good track record so far with NEU and TLX.
I’m pretty sure it’s been shared before but check out this YouTube video which directed me to SNT and motivated my purchase.
It seems like his next round of investments are SNT and Curvebeam.
His fund ethos is “buying late stage business, but at a preclinical price.”
That’s what has drawn me to this stock, it’s crazy to think we’re only valued at $42.5m with several Ph2 and Ph1 trial results to drop in the next 6-12 months! You would think a positive Ph2 would take this to $150-200m MC and beyond.
Add to My Watchlist
What is My Watchlist?
